Across TCGA pan-cancer cohorts, SPATA12 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated SPATA12 data layer compared with 2 for mutation status.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SPATA12 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA12 expression acts as an unfavorable survival marker, although some lineages such as KIRP and HNSC show a favorable association.
KIRP, HNSC, and LGG are the cancer types where SPATA12 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.